CAMK2G — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL232042	1.00	5/20
SCHEMBL234334	1.00	5/20
SCHEMBL147422	0.66	4/20
SCHEMBL144979	0.56	4/20
Riviciclib (SCHEMBL290347)	1.00	3/20
Bi-2536 (SCHEMBL372489)	1.00	3/20
Riviciclib (SCHEMBL290572)	0.98	3/20
Riviciclib (SCHEMBL291157)	0.98	3/20
SCHEMBL375839	0.85	3/20
SCHEMBL375825	0.83	3/20
SCHEMBL376040	0.83	3/20
SCHEMBL376100	0.81	3/20
SCHEMBL376093	0.81	3/20
SCHEMBL375746	0.76	3/20
SCHEMBL375828	0.76	3/20
SCHEMBL375952	0.76	3/20
SCHEMBL375964	0.74	3/20
SCHEMBL376097	0.74	3/20
SCHEMBL291051	0.74	3/20
SCHEMBL291052	0.74	3/20

Clinical trials — most relevant to CAMK2G by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
COMS for Chronic Ulcers Treatment	PHASE4	RECRUITING
The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction	PHASE2	ACTIVE_NOT_RECRUITING
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients	PHASE2	WITHDRAWN
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Epithelioid Haemangioendothelioma Observational Study	nan	RECRUITING
Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia	nan	RECRUITING
Calmodulin Gene Mutations in Patients With Ventricular Arrhythmia of Unknown Origin - A Screening Study	nan	WITHDRAWN
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life	nan	COMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Human Epilepsy Genetics--Neuronal Migration Disorders Study	nan	RECRUITING
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Biomarkers of CASH	nan	ACTIVE_NOT_RECRUITING
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease	nan	UNKNOWN
Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs	nan	WITHDRAWN
Urine Concentration of S100B in Extremely Premature Infants	nan	COMPLETED
Genes, Proteins, and Metabolites in Drug-resistant Epilepsy (DRE) Patients	nan	NOT_YET_RECRUITING
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CAMK2G binder may also engage these)

Protein	Name	Similarity
P11730	—	1.000	P11730 →
P08413	—	1.000	P08413 →
CAMK2D	Calcium/calmodulin-dependent protein kinase type II subunit delta	1.000	landscape →
Q923T9	—	1.000	Q923T9 →
Q2HJF7	—	1.000	Q2HJF7 →
Q6DEH3	—	0.999	Q6DEH3 →
Q95266	—	0.999	Q95266 →
Q6DGS3	—	0.998	Q6DGS3 →
O77708	—	0.998	O77708 →
Q3MHJ9	—	0.998	Q3MHJ9 →
P15791	—	0.998	P15791 →
A8WXF6	—	0.998	A8WXF6 →
P28652	—	0.998	P28652 →
Q6PHZ2	—	0.997	Q6PHZ2 →
Q5RCC4	—	0.995	Q5RCC4 →
P11275	—	0.995	P11275 →
Q00168	—	0.994	Q00168 →
P11798	—	0.994	P11798 →
P13234	—	0.994	P13234 →
Q5ZKI0	—	0.993	Q5ZKI0 →
Q9DG02	—	0.993	Q9DG02 →
CAMK2A	Calcium/calmodulin-dependent protein kinase type II subunit alpha	0.993	landscape →
Q8BRK8	—	0.993	Q8BRK8 →
CAMK4	Calcium/calmodulin-dependent protein kinase type IV	0.991	landscape →
O08875	—	0.991	O08875 →
DAPK1	Death-associated protein kinase 1	0.991	landscape →
Q9N3Z3	—	0.991	Q9N3Z3 →
Q6PFQ0	—	0.991	Q6PFQ0 →
Q80YE7	—	0.991	Q80YE7 →
Q66I46	—	0.990	Q66I46 →